Clinical Trials Logo

Clinical Trial Summary

The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.


Clinical Trial Description

Participants for whom there are no other appropriate therapeutic options and who are not eligible to enroll in other tabelecleucel clinical studies, may be enrolled in this study. After the screening period, participants will receive intravenous infusions of tabelecleucel (1.6 to 2 × 10^6cells/kg) on Day 1, Day 8, and Day 15 of every 35-day cycle. Clinical assessment of disease response is recommended approximately 15 days after the last dose of tabelecleucel to assess the need for additional treatment. The end of expanded access protocol (EAP) visit should be performed at 30 days after the last dose of tabelecleucel. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02822495
Study type Expanded Access
Source Atara Biotherapeutics
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Recruiting NCT06080490 - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT03871296 - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Not yet recruiting NCT06022445 - Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
Recruiting NCT04502628 - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT N/A
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Completed NCT03454568 - The Patients' Experience After Stem Cell Transplant
Recruiting NCT05466201 - The Use of Eltrombopag Post HSCT in BMFS Phase 2/Phase 3
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Recruiting NCT05523336 - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed NCT03355235 - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed NCT04888286 - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Not yet recruiting NCT05421416 - Loratadine for the Prevention of G-CSF-related Bone Pain Phase 2
Recruiting NCT04167683 - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Active, not recruiting NCT03967665 - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution Phase 3
Withdrawn NCT05104268 - Study of a New Medical Device for Oral Mucositis Early Phase 1
Recruiting NCT04623424 - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Completed NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Phase 4